We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
Read MoreHide Full Article
MEDNAX, Inc. (MD - Free Report) reported first-quarter 2020 adjusted earnings of 32 cents per share, missing the Zacks Consensus Estimate by 23.8%. Moreover, the bottom line plunged 50.8% year over year.
The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenue.
The company generated revenues of $846 million, which missed the Zacks Consensus Estimate by 0.6%. Also, the top line slid 0.6% from the year-ago period.
Same unit revenues dipped 1% year over year.
General and administrative expenses inched 3.3% to $105.2 million due to higher general and administrative expenses.
Interest expense of the company declined 10.1% to $27.6 million on the back of lower borrowings.
In the quarter under review, EBITDA totaled $63.4 million, down 39.6% year over year.
The company invested $13.7 million in capital expenditures.
Withdrawal of Preliminary Outlook
Given the current pandemic-led uncertainty, the company scrapped its previously-announced quarterly and 2020 outlook.
Financial Update
As of Mar 31, 2020, the company had cash and cash equivalents of $312 million, up 177% from the level at 2019 end.
The company’s total debt of $2.1 billion was up 21.5% from the level at 2019 end while total assets worth $4.3 billion rose 4.2% from the level at 2019 end.
Cash flow used in operating activities was $146.4 million in the quarter under review, jumping 142.4% year over year.
Of the other players from the same space that reported first-quarter results so far, Tenet Healthcare Corporation’s (THC - Free Report) bottom line beat the Zacks Consensus Estimate while that of HCA Healthcare Inc (HCA - Free Report) and Universal Health Services Inc (UHS - Free Report) missed the mark.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
MEDNAX, Inc. (MD - Free Report) reported first-quarter 2020 adjusted earnings of 32 cents per share, missing the Zacks Consensus Estimate by 23.8%. Moreover, the bottom line plunged 50.8% year over year.
The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenue.
MEDNAX Inc Price and EPS Surprise
MEDNAX Inc price-eps-surprise | MEDNAX Inc Quote
Quarterly Details
The company generated revenues of $846 million, which missed the Zacks Consensus Estimate by 0.6%. Also, the top line slid 0.6% from the year-ago period.
Same unit revenues dipped 1% year over year.
General and administrative expenses inched 3.3% to $105.2 million due to higher general and administrative expenses.
Interest expense of the company declined 10.1% to $27.6 million on the back of lower borrowings.
In the quarter under review, EBITDA totaled $63.4 million, down 39.6% year over year.
The company invested $13.7 million in capital expenditures.
Withdrawal of Preliminary Outlook
Given the current pandemic-led uncertainty, the company scrapped its previously-announced quarterly and 2020 outlook.
Financial Update
As of Mar 31, 2020, the company had cash and cash equivalents of $312 million, up 177% from the level at 2019 end.
The company’s total debt of $2.1 billion was up 21.5% from the level at 2019 end while total assets worth $4.3 billion rose 4.2% from the level at 2019 end.
Cash flow used in operating activities was $146.4 million in the quarter under review, jumping 142.4% year over year.
Zacks Rank
MEDNAX currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Players
Of the other players from the same space that reported first-quarter results so far, Tenet Healthcare Corporation’s (THC - Free Report) bottom line beat the Zacks Consensus Estimate while that of HCA Healthcare Inc (HCA - Free Report) and Universal Health Services Inc (UHS - Free Report) missed the mark.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>